2025
Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Paul C, Papp K, Colombo M, Scotto J, Vaile J, Zhuo J, Vritzali E, Berger V, Schroeder G, Banerjee S, Thaçi D, Strober B. Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials. Journal Of The European Academy Of Dermatology And Venereology 2025 PMID: 40045918, DOI: 10.1111/jdv.20553.Peer-Reviewed Original ResearchLong-term extension trialsLong-term extensionModerate to severe plaque psoriasisSevere plaque psoriasisPlaque psoriasisAdverse eventsTyrosine kinase 2Person yearsData cut-offYear of treatmentAdverse cardiovascular eventsTreatment of adultsPatient-reported outcomesSystemic therapyHerpes zosterSafety profileVenous thromboembolismDeucravacitinibCardiovascular eventsEfficacy resultsPatientsPsoriasisOutcome ratesExtension trialParent trialOutcomes of Mechanical Thrombectomy for Acute Limb Ischemia at a Tertiary Referral Center
Loh S, Nasir A, Strosberg D, Ochoa Chaar C, Guzman R, Tonnessen B. Outcomes of Mechanical Thrombectomy for Acute Limb Ischemia at a Tertiary Referral Center. Journal Of Vascular Surgery 2025 PMID: 40024380, DOI: 10.1016/j.jvs.2025.02.027.Peer-Reviewed Original ResearchTertiary referral centerAcute limb ischemiaAdverse cardiovascular eventsReferral centerMechanical thrombectomyOpen surgeryThirty-dayCardiovascular eventsConversion to open surgeryLimb ischemiaTreated with mechanical thrombectomyMedian follow-upCatheter-directed thrombolysisManagement of acute limb ischemiaDuration of symptomsThirty-day complicationsOutcomes of mechanical thrombectomyRisk of limb lossHigh risk of limb lossAcute limb ischemia casesMechanical thrombectomy devicesBleeding eventsMulticenter trialThrombosed bypassesThrombosed stentThirty-day postoperative cardiopulmonary complications in sarcoidosis: Insights from a retrospective matched cohort analysis
Freund J, Gosalvez C, Rady A, Notarianni A, Carr Z. Thirty-day postoperative cardiopulmonary complications in sarcoidosis: Insights from a retrospective matched cohort analysis. Anesthesiology And Perioperative Science 2025, 3: 9. DOI: 10.1007/s44254-025-00087-5.Peer-Reviewed Original ResearchPostoperative pulmonary complicationsPostoperative cardiopulmonary complicationsLength of staySarcoidosis patientsSarcoidosis diagnosisCardiopulmonary complicationsCohort analysisAssociated with 30-day MACEIndependent of disease stageSystemic granulomatous disorderRetrospective matched cohort analysisMethodsThis retrospective studyAssociated with higher riskCongestive heart failure eventsComparative cohort analysisHeart failure eventsPreoperative chest radiographyAdverse cardiovascular eventsMatched cohort analysisCompared to controlsPulmonary complicationsSarcoidosis cohortGranulomatous disorderLung involvementThirty-daySex Differences in the Safety and Efficacy of Different Durations of DAPT After PCI
Park D, Mahajan S, Fishman E, Ambrosini A, Acero L, Hu J, Campbell G, Babapour G, Kelsey M, Douglas P, Gupta A, Frampton J, Nanna M. Sex Differences in the Safety and Efficacy of Different Durations of DAPT After PCI. JACC Advances 2025, 4: 101543. PMID: 39886301, PMCID: PMC11780104, DOI: 10.1016/j.jacadv.2024.101543.Peer-Reviewed Original ResearchMonths of DAPTDuration of dual antiplatelet therapyNet adverse clinical eventsDuration of DAPTRandomized controlled trialsPercutaneous coronary interventionShorter duration of dual antiplatelet therapyRisk of bleedingBleeding riskLow risk of bleedingSex-based differencesAssociated with lower riskAdverse clinical eventsDual antiplatelet therapyAdverse cardiovascular eventsNetwork meta-analysisWeb of Science databasesAntiplatelet therapyClinical impactCardiovascular eventsClinical eventsSystematic reviewSignificant sex-based differencesControlled trialsCoronary interventionSafety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years
Armstrong A, Lebwohl M, Warren R, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Kisa R, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo M, Scotto J, Banerjee S, Strober B, Thaçi D, Blauvelt A. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years. JAMA Dermatology 2025, 161: 56-66. PMID: 39602111, PMCID: PMC11736510, DOI: 10.1001/jamadermatol.2024.4688.Peer-Reviewed Original ResearchLong-term extension trialsExposure-adjusted incidence ratesSevere plaque psoriasisLong-term extensionModerate to severe plaque psoriasisAdverse eventsPlaque psoriasisDouble-blind phase 3 trialStatic Physician's Global Assessment scoreDiscontinuation due to adverse eventsDay 1Physician Global Assessment scoreIncidence rateEffective long-term treatmentUpper respiratory tract infectionClinical response rateGlobal Assessment scorePhase 3 trialRespiratory tract infectionsWeeks of treatmentYear of treatmentLong-term treatmentAdverse cardiovascular eventsLong-term safetyCumulative period
2024
SoutheAsTern eUrope microciRculATION (SATURATION) registry - Design and rationale
Odanovic N, Tsioufis K, Dimitriadis K, Sakalidis A, Papafaklis M, Davlouros P, Ivanov I, Cankovic M, Kalogeropoulos A, Hamilos M, Sideras E, Konigstein M, Zornitzki L, Kovarnik T, Ruzsa Z, Piroth Z, Zdravkovic M, Mehmedbegovic Z, Miovski Z, Jurin H, Kanovsky J, Regev E, Shah S, Ilic I, investigators S. SoutheAsTern eUrope microciRculATION (SATURATION) registry - Design and rationale. Cardiovascular Revascularization Medicine 2024 PMID: 39672766, DOI: 10.1016/j.carrev.2024.11.012.Peer-Reviewed Original ResearchSeattle Angina QuestionnairePatient-centered outcomesEQ-5D-5LQuality of lifeAngina QuestionnaireCoronary function testingInvasive physiologic evaluationMajor adverse cardiovascular eventsStages of coronary artery diseaseCoronary microvascular dysfunctionInvasive coronary physiological assessmentAdverse cardiovascular eventsPotential interventionsSigns of ischemiaCoronary artery diseaseCardiac catheterization labEvaluation of microcirculationDegree of coronary atherosclerosisRegistryCoronary physiology assessmentClinical practiceSymptomatic patientsCardiovascular riskPatient selectionMicrovascular dysfunctionComplete revascularization versus culprit‐only revascularization in older adults with ST‐elevation myocardial infarction: Systematic review and meta‐analysis of randomized controlled trials
Park D, Hu J, Frampton J, Rymer J, Al Damluji A, Nanna M. Complete revascularization versus culprit‐only revascularization in older adults with ST‐elevation myocardial infarction: Systematic review and meta‐analysis of randomized controlled trials. Journal Of The American Geriatrics Society 2024, 73: 874-880. PMID: 39639558, PMCID: PMC11908960, DOI: 10.1111/jgs.19295.Peer-Reviewed Original ResearchContrast-associated acute kidney injuryST-elevation myocardial infarctionCulprit-only revascularizationRandomized controlled trialsComplete revascularizationHazard of MACEMeta-analysisOlder adultsHazard ratioClass III to class IMeta-analysis of randomized controlled trialsAssociated with reduced MACEMyocardial infarctionControlled trialsAcute kidney injuryRandomized controlled trials of CRAdverse cardiovascular eventsBenefits of CRComplexity of lesionsRandom-effects modelBleeding riskKidney injuryMeta-analysis to dateCardiovascular eventsSubgroup analysisAdverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors
Kwan J, Shen M, Akhlaghi N, Hu J, Mora R, Cross J, Jiang M, Mankbadi M, Wang P, Zaman S, Lee S, Im Y, Feher A, Liu Y, S. S, Tao W, Wei W, Baldassarre L. Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors. PLOS ONE 2024, 19: e0314555. PMID: 39621799, PMCID: PMC11611253, DOI: 10.1371/journal.pone.0314555.Peer-Reviewed Original ResearchConceptsAdverse cardiovascular eventsICI therapyCardiac magnetic resonanceIncreased risk of mortalityICI initiationIncreased riskRisk of mortalityCentral nervous systemVentricular dysfunctionCancer patients treated with ICIsCardiovascular eventsLeft ventricular late gadolinium enhancementMortality benefitCardiovascular riskAbnormal left ventricular ejection fractionPatients treated with ICIsLeft ventricular ejection fractionCentral nervous system malignanciesRisk of adverse cardiovascular eventsImmune checkpoint inhibitorsRight ventricular dysfunctionGlobal longitudinal strainVentricular ejection fractionLeft ventricular dysfunctionMultimodality cardiac imagingTreating Migraine Patients With Cardiovascular Risks
Wang K, Sico J. Treating Migraine Patients With Cardiovascular Risks. Neurology 2024, 103: e210196. PMID: 39621947, DOI: 10.1212/wnl.0000000000210196.Peer-Reviewed Original ResearchNonaspirin nonsteroidal anti-inflammatory drugsCardiovascular safety profileSafety profileCardiovascular eventsCardiovascular riskIncreased riskIncreased risk of ischemic eventsRisk of ischemic eventsNonsteroidal anti-inflammatory drugsExclusion of patientsAdverse cardiovascular eventsMyocardial infractionRisk of acute cardiovascular eventsEffective acute treatmentTreat migraine patientsRisk of myocardial infractionCOX-2 inhibitorsAnti-inflammatory drugsAcute cardiovascular eventsMigraine patientsAcute treatmentIschemic eventsManaging cardiovascular riskRandomized trialsCOX-2Brodalumab: Six-Year US Pharmacovigilance Report
Lebwohl M, Koo J, Armstrong A, Strober B, Yoon S, Rawnsley N, Goehring E, Mangin G, Jacobson A. Brodalumab: Six-Year US Pharmacovigilance Report. Dermatology And Therapy 2024, 15: 213-222. PMID: 39589679, PMCID: PMC11785849, DOI: 10.1007/s13555-024-01304-y.Peer-Reviewed Original ResearchAdverse eventsSystemic therapyUS patientsCase of Candida infectionSafety profile of brodalumabSafety of brodalumabMajor adverse cardiovascular eventsInterleukin-17 receptorAdverse cardiovascular eventsLong-term safetyFungal infection rateCandida infectionsPlaque psoriasisSafety profileAdult patientsBrodalumabCardiovascular eventsBox warningPharmacovigilance reportsFungal infectionsClinical trialsPatientsPharmacovigilance dataMedDRA QueriesClinical practiceDeucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Colombo M, Vaile J, Vritzali E, Hoyt K, Daamen C, Banerjee S, Strober B, Thaçi D, Blauvelt A. Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s423. DOI: 10.25251/skin.8.supp.423.Peer-Reviewed Original ResearchAssess adverse eventsLong-term extensionModerate to severe plaque psoriasisExposure-adjusted incidence ratesSevere plaque psoriasisPlaque psoriasisLong-term extension trialsClinical response rateParent trialAdverse cardiovascular eventsTreatment of adultsSystemic therapyEfficacy outcomesHerpes zosterSafety profileVenous thromboembolismAdverse eventsDeucravacitinibEfficacy resultsCardiovascular eventsSafety signalsPatientsResponse rateIncidence ratePsoriasisPrognostic significance of phase analysis using SPECT myocardial perfusion imaging in heart failure: a systematic review and meta-analysis
Lee K, Han S, Ryu J, Cho S, Moon D. Prognostic significance of phase analysis using SPECT myocardial perfusion imaging in heart failure: a systematic review and meta-analysis. The International Journal Of Cardiovascular Imaging 2024, 41: 27-35. PMID: 39535673, DOI: 10.1007/s10554-024-03278-6.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiac-Gated Single-Photon Emission Computer-Assisted TomographyFemaleHeart FailureHumansMaleMiddle AgedMyocardial Perfusion ImagingPredictive Value of TestsPrognosisRisk AssessmentRisk FactorsTomography, Emission-Computed, Single-PhotonVentricular Dysfunction, LeftVentricular Function, LeftConceptsLeft ventricular mechanical dyssynchronyMyocardial perfusion SPECTHF patientsCardiac deathHeart failurePrognostic significancePrognostic valueGated SPECTPerfusion SPECTPooled HRMeta-analysisHazard ratioSPECT myocardial perfusion imagingAll-causeVentricular mechanical dyssynchronyAdverse cardiac eventsMyocardial perfusion imagingAdverse cardiovascular eventsPublication biasConfidence intervalsAnalysis of SPECTSystematic reviewRandom-effects modelMechanical dyssynchronyPrognostic factorsThe Impact of Frailty on Patients With AF and HFrEF Undergoing Catheter Ablation A Nationwide Population Study
Mark J, Colombo R, Alfonso C, Llanos A, Collado E, Larned J, Giese G, Dyal M, Nanna M, Damluji A. The Impact of Frailty on Patients With AF and HFrEF Undergoing Catheter Ablation A Nationwide Population Study. JACC Advances 2024, 3: 101358. PMID: 39600986, PMCID: PMC11588852, DOI: 10.1016/j.jacadv.2024.101358.Peer-Reviewed Original ResearchAdverse cardiovascular eventsCatheter ablationAtrial fibrillationCardiovascular eventsHeart failureFrail patientsHospital lengthNonfrail patientsReducing major adverse cardiovascular eventsAssociated with worse outcomesMajor adverse cardiovascular eventsReduced ejection fractionHospital length of stayIn-hospital mortalityLonger hospital lengthAssociated with increased oddsDischarge dispositionInfluence of frailtyMultivariate regression analysisNationwide Inpatient SampleImpact of frailtyLength of stayPrevalence of frailtyEjection fractionJohns Hopkins Adjusted Clinical GroupsThe Updated Registry of Fast Myocardial Perfusion Imaging with Next-Generation SPECT (REFINE SPECT 2.0).
Miller R, Lemley M, Shanbhag A, Ramirez G, Liang J, Builoff V, Kavanagh P, Sharir T, Hauser M, Ruddy T, Fish M, Bateman T, Acampa W, Einstein A, Dorbala S, Di Carli M, Feher A, Miller E, Sinusas A, Halcox J, Martins M, Kaufmann P, Dey D, Berman D, Slomka P. The Updated Registry of Fast Myocardial Perfusion Imaging with Next-Generation SPECT (REFINE SPECT 2.0). Journal Of Nuclear Medicine 2024, 65: 1795-1801. PMID: 39362762, PMCID: PMC11533915, DOI: 10.2967/jnumed.124.268292.Peer-Reviewed Original ResearchCoronary artery calciumCT attenuation correction imagesStress total perfusion deficitMyocardial perfusion imagingTotal perfusion deficitAttenuation correction imagesPerfusion imagingREFINE SPECTImprove prediction of adverse outcomesPerfusion deficitsSPECT myocardial perfusion imagingIncreased risk of MACEPredictive of adverse outcomesMedian follow-upInvasive coronary angiographyRisk of MACEAdverse cardiovascular eventsCAC scoreExperience MACECoronary angiographyArtery calciumInternational registryCardiovascular eventsFollow-upClinical dataLong-term outcomes of ischaemia with no obstructive coronary artery disease (INOCA): a systematic review and meta-analysis
Odanović N, Schwann A, Zhang Z, Kapadia S, Kunnirickal S, Parise H, Tirziu D, Ilic I, Lansky A, Pietras C, Shah S. Long-term outcomes of ischaemia with no obstructive coronary artery disease (INOCA): a systematic review and meta-analysis. Open Heart 2024, 11: e002852. PMID: 39353703, PMCID: PMC11448144, DOI: 10.1136/openhrt-2024-002852.Peer-Reviewed Original ResearchConceptsCoronary Vasomotor Disorders International Study GroupRate of MACEReduced coronary flow reserveCoronary flow reservePrognosis of patientsVasospastic anginaPatient yearsMyocardial infarctionPrimary outcomeIncidence of primary outcomeLong-term prognosis of patientsSystematic reviewMeta-analysisLong-term prognosisInternational Study GroupAdverse cardiovascular eventsLong-term outcomesImaging stress testsMeta-analysis of studiesRandom-effects modelWeb of ScienceINOCACardiovascular eventsFollow-upVasomotor disordersS2086 Outcomes After Major Adverse Cardiovascular Events in MASLD Patients: A Nationwide Inpatient Sample Study
Ameyaw P, Boateng S, Boampong A, Ugwendum D, Zinyandu T, Opoku I, Ahmed A, Njei B. S2086 Outcomes After Major Adverse Cardiovascular Events in MASLD Patients: A Nationwide Inpatient Sample Study. The American Journal Of Gastroenterology 2024, 119: s1489-s1490. DOI: 10.14309/01.ajg.0001037712.96310.7f.Peer-Reviewed Original ResearchMajor adverse cardiovascular eventsAdverse cardiovascular eventsComparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM
Khera R, Aminorroaya A, Dhingra L, Thangaraj P, Pedroso Camargos A, Bu F, Ding X, Nishimura A, Anand T, Arshad F, Blacketer C, Chai Y, Chattopadhyay S, Cook M, Dorr D, Duarte-Salles T, DuVall S, Falconer T, French T, Hanchrow E, Kaur G, Lau W, Li J, Li K, Liu Y, Lu Y, Man K, Matheny M, Mathioudakis N, McLeggon J, McLemore M, Minty E, Morales D, Nagy P, Ostropolets A, Pistillo A, Phan T, Pratt N, Reyes C, Richter L, Ross J, Ruan E, Seager S, Simon K, Viernes B, Yang J, Yin C, You S, Zhou J, Ryan P, Schuemie M, Krumholz H, Hripcsak G, Suchard M. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM. Journal Of The American College Of Cardiology 2024, 84: 904-917. PMID: 39197980, PMCID: PMC12045554, DOI: 10.1016/j.jacc.2024.05.069.Peer-Reviewed Original ResearchConceptsGLP-1 RAsSecond-line agentsGLP-1Antihyperglycemic agentsCardiovascular diseaseMACE riskGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsEffects of SGLT2isType 2 diabetes mellitusPeptidase-4 inhibitorsAdverse cardiovascular eventsCox proportional hazards modelsRandom-effects meta-analysisCardiovascular risk reductionTarget trial emulationProportional hazards model683 - Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study
Bunick C, Grada A, Del Rosso J, Armstrong A, Yue E, Krueger W. 683 - Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study. British Journal Of Dermatology 2024, 191: ljae266.057. DOI: 10.1093/bjd/ljae266.057.Peer-Reviewed Original ResearchRisk of MACEModerate-to-severe diseaseIncidence of MACEMACE riskAdverse cardiovascular eventsAtopic dermatitisMatched controlsRheumatoid arthritisCardiovascular diseaseCardiovascular eventsModerate-to-severe atopic dermatitisAssociated with increased MACE riskRelative risk of MACEMultivariate Cox proportional hazards modelRelative riskCohort entry dateModerate-to-severe ADHistory of cardiovascular diseaseAssociated with multiple comorbiditiesIncreased MACE riskHistory of smokingChronic systemic inflammationFollow-up periodCox proportional hazards modelsUS administrative claims dataImpact of Multiarterial Revascularization on Long-term Major Adverse Cardiovascular Events After Coronary Bypass in 23,798 Patients
Jameie M, Valinejad K, Pashang M, Jameie M, Bagheri J, Soleimani H, Jalali A, Mehrabanian M, Nayebirad S, Abbasi K, Masoudkabir F, Tajdini M, Mehrani M, Movahedi N, Hameed I, Hosseini K, Gaudino M. Impact of Multiarterial Revascularization on Long-term Major Adverse Cardiovascular Events After Coronary Bypass in 23,798 Patients. The Annals Of Thoracic Surgery 2024, 118: 863-872. PMID: 39009058, DOI: 10.1016/j.athoracsur.2024.06.034.Peer-Reviewed Original ResearchInverse probability weightingRisks of study outcomesAssociated with reduced riskRisk factorsCovariate-adjusted modelsPatient subgroupsAll-cause mortalitySingle-center retrospective cohort studyCardiovascular risk factorsLong-term major adverse cardiovascular eventsAdverse cardiocerebrovascular eventsMajor adverse cardiovascular eventsRetrospective cohort studyRisk of adverse eventsAdverse cardiovascular eventsArtery bypass graftingCohort studyPost-surgery outcomesSaphenous vein graftsStudy outcomesStudy populationCrude mortalityCardiocerebrovascular eventsProbability weightingUnivariate levelThe Predictive Value of Aortic Calcification on Computed Tomography for Major Cardiovascular Events
Chlorogiannis D, Pargaonkar S, Apostolos A, Vythoulkas-Biotis N, Kokkinidis D, Nagraj S. The Predictive Value of Aortic Calcification on Computed Tomography for Major Cardiovascular Events. Journal Of Clinical Medicine 2024, 13: 4019. PMID: 39064058, PMCID: PMC11277087, DOI: 10.3390/jcm13144019.Peer-Reviewed Original ResearchTranscatheter aortic valve implantationPrediction of MACEAortic calcificationComputed tomographyPredictive valueCardiovascular diseaseAbdominal aortic calcificationTranscatheter aortic valve implantation proceduresDescending thoracic aortaAdverse cardiovascular eventsIdentification of patientsPrevalence of cardiovascular diseaseExtra-coronary calcificationAortic valve implantationAtherosclerotic cardiovascular diseaseMinimally invasive percutaneous proceduresInvasive percutaneous proceduresThoracic calcificationDiagnostic modalitiesAortic archRisk stratificationAortic valveCardiovascular eventsCoronary calcificationThoracic aorta
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply